RA
VIR icon

Royce & Associates’s Vir Biotechnology VIR Stock Holding History

Royce & Associates’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-102,900
Closed -$916K – 912
2024
Q2 		$916K Hold
102,900
– – 0.01% 727
2024
Q1 		$1.04M Hold
102,900
– – 0.01% 720
2023
Q4 		$1.04M Hold
102,900
– – 0.01% 735
2023
Q3 		$964K Sell
102,900
-4,923
-5% -$70.2K 0.01% 744
2023
Q2 		$2.64M Buy
107,823
+56,516
+110% +$1.42M 0.03% 628
2023
Q1 		$1.19M Sell
51,307
-5,596
-10% -$143K 0.01% 740
2022
Q4 		$1.44M Buy
56,903
+28,595
+101% +$701K 0.02% 697
2022
Q3 		$546K Buy
+28,308
New +$720K 0.01% 807

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Royce & Associates's VIR Position: Q3 2024 in Review

Royce & Associates sold out of Vir Biotechnology (VIR) in Q3 2024, closing a stake of 102,900 shares — an estimated $916K sold.

Royce & Associates first reported a position in VIR in Q3 2022 and held it in 8 quarters. The position peaked at $2.64M in Q2 2023. 197 funds tracked by Wall St. Rank hold VIR as of Q3 2024.

  • Royce & Associates reported no remaining Vir Biotechnology position as of Q3 2024 after selling out during the quarter.
  • Royce & Associates sold 102,900 Vir Biotechnology shares in Q3 2024, an estimated $916K.
  • Royce & Associates first reported a position in Vir Biotechnology in Q3 2022 and held it in 8 quarters.
  • Royce & Associates's Vir Biotechnology position peaked at $2.64M in Q2 2023.
  • 197 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2024.

Based on Royce & Associates's 13F filing for Q3 2024, filed 6 Nov 2024.